Navigation Links
Janssen Therapeutics Announces Recipient of Its Second Point Scholarship for LGBT Students
Date:7/16/2013

TITUSVILLE, N.J., July 16, 2013 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen) announced today the recipient of the second scholarship the company is supporting through the Point Foundation, the nation's largest scholarship-granting organization for lesbian, gay, bisexual and transgender (LGBT) students of merit. Janssen is the first pharmaceutical company to fund a Point Scholarship.  

The Point Scholarship supported by Janssen is for LGBT students whose field of study is focused on HIV/AIDS, or who have chosen to attend business school. It has been awarded to Michael Haymer of Orange County, California. Michael is pursuing a joint MD-MBA degree from the PRIME Program at the David Geffen School of Medicine at University of California, Los Angeles (UCLA).

The Point Scholarship is granted for a four-year period to graduating high school seniors and college students. As a Point Scholar, Michael will receive financial assistance and will be matched with a successful professional who can serve as his mentor and role model.

Michael and his four siblings were raised by their single mother who died from complications of undertreated diabetes during his first year of medical school. As a tribute to her, Michael focused his studies on serving under-resourced and vulnerable populations. 

"I'm personally committed to my research and work as a community educator in the areas of LGBT and HIV health because I know firsthand how important it is to give a voice to underserved populations," said Michael. "With this scholarship, I look forward to setting an example for other LGBT students interested in healthcare and continuing the tradition of Point Scholars."

Michael has a particular interest in the area of transgender healthcare. He directed the LGBT Health Student Symposium, which hosted more than 100 students from across the country. In recognition of his efforts, Michael received the UCLA Diversity, Equity & Inclusion Award.  

Michael also has experience in HIV research; he served as a community educator for an international HIV vaccine trial and conducted research on the use of mobile technology to improve community outreach methods for HIV/AIDS prevention.

In 2012, Janssen provided a Point Scholarship to medical student Siddarth (Sid) Puri to support his studies at University of California Davis School of Medicine. Sid was named co-director, class of 2014, of the student-run Joan Viteri Memorial Clinic dedicated to serving the healthcare needs of uninsured drug users. The Point Scholarship helps Sid advance his efforts to provide culturally sensitive medical care to the LGBT community and people living with HIV/AIDS.

"Since the start of the HIV epidemic, the LGBT community has played a leadership role in mobilizing the response. While great progress has been made, more than 30 years later HIV infection rates are rising among men who have sex with men and communities of color," said Ron Falcon, MD, Director of Marketing, HIV, Janssen. "Through the Point Foundation scholarship, Janssen is investing to help develop the next generation of leaders from the LGBT community to continue the fight against HIV."

About Janssen Therapeutics
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in HIV and other infectious diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Headquartered in Titusville, New Jersey, Janssen Therapeutics, Division of Janssen Products, LP, is one of the Janssen Pharmaceutical Companies. Visit http://www.janssentherapeutics.com for more information and follow us on Twitter at @JanssenUS.

Media Contact:
Pamela Van Houten
Phone: (609) 730-7902
Email: pvanhou5@its.jnj.com


'/>"/>
SOURCE Janssen Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Second Genome Announces Agreement with Janssen on Microbiome Drug Discovery in Ulcerative Colitis
2. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
3. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
4. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
5. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
6. Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
7. Janssen Pharmaceutica, NV, Funds New Global Mental Health Scholarships as Part of Its Healthy Minds Program
8. Janssen Neuroscientists and Colleagues Challenge Healthcare Industry to Create Integrated Approaches to Healthcare Innovation in Newly Published Article
9. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
10. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
11. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
Breaking Medicine News(10 mins):